A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies

Keywords : toxicity therapeutic use 80 and over therapy Adult adverse effects B-Cell Chronic B-Lymphocytes Diffuse Cohort Studies blood Diarrhea drug effects drug therapy Female Imidazoles France Hematoma Hematology Humans Large B-Cell Local Leukemia London Lymphocytic Male Mantle-Cell pathology Neoplasm Recurrence Lymphoma Medicine Patients Pyrimidines Protein Kinase Inhibitors Protein-Tyrosine Kinases antagonists & inhibitors Aged Middle Aged